Skip to main content

KMDA

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

KMDA Price
Price Chart

Forward-looking statistics

Beta
0.65
Risk
42.05%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees305
Market cap$290.8M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+2.2
Liquidity+0.7
Inflation-0.7
Commodities-0.6
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio22.16
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Is Kamada (KMDA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 4, 2025)
Kamada: Q3 Earnings Insights

Kamada (NASDAQ:KMDA) reported its Q3 earnings results on Monday, November 22, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga (November 22, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free